HighTower Advisors
ELTX icon

HighTower Advisors’s Elicio Therapeutics ELTX Stock Holding History

HighTower Advisors’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$119K Sell
11,166
-20
-0.2% -$193 ﹤0.01% 3602
2025
Q4 		$89K Buy
+11,186
New +$102K ﹤0.01% 3521
2022
Q4 		– Sell
-1,357
Closed -$12K – 3391
2022
Q3 		$12K Buy
+1,357
New +$14.2K ﹤0.01% 3003

Other funds holding ELTX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HighTower Advisors's ELTX Position: Q1 2026 in Review

HighTower Advisors reduced its Elicio Therapeutics (ELTX) stake by 0.18% in Q1 2026, selling an estimated $193 and leaving 11,166 shares worth $119K. The position accounts for ﹤0.01% of the portfolio, ranked #3602.

HighTower Advisors first reported a position in ELTX in Q3 2022 and has held it in 3 quarters since. 47 funds tracked by Wall St. Rank hold ELTX as of Q1 2026.

  • HighTower Advisors held 11,166 shares of Elicio Therapeutics worth $119K as of Q1 2026.
  • HighTower Advisors sold 20 Elicio Therapeutics shares in Q1 2026, an estimated $193.
  • Elicio Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #3602 holding.
  • HighTower Advisors first reported a position in Elicio Therapeutics in Q3 2022 and has held it in 3 quarters since.
  • 47 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.